From “blockbusters” to “biosimilars”: An opportunity for patients, medical specialists and health care providers
Advances in basic research and research and development plans of pharmaceutical companies are radically changing the kind of available drugs and therapeutic targets. We are switching from predominantly chemical molecules, aimed at treating large populations of patients (blockbuster drugs), to a new...
Uloženo v:
| Vydáno v: | Pulmonary pharmacology & therapeutics Ročník 25; číslo 6; s. 483 - 486 |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
England
Elsevier Ltd
01.12.2012
|
| Témata: | |
| ISSN: | 1094-5539, 1522-9629, 1522-9629 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Advances in basic research and research and development plans of pharmaceutical companies are radically changing the kind of available drugs and therapeutic targets. We are switching from predominantly chemical molecules, aimed at treating large populations of patients (blockbuster drugs), to a new generation of products, mostly biotech, aimed at modifying a specific pathogenetic mechanism. In other word we are moving fast to targeted therapy, which represents the first step toward personalized therapy, where the right drug at the right dose is administered to the right person, at the right time.
Like the patent expiration of chemical products has corresponded to the development of generic drugs, the expiration of new biotech products will witness the appearance of biosimilars. The latter are biologic products that are highly similar but not identical to the reference medical products in terms of quality, safety and efficacy. This implies specific research, clinical monitoring, physicians updating of knowledge for a safe and appropriate use of these products.
We are the beginning of a devolution in patient's care and physicians' practice. |
|---|---|
| AbstractList | Advances in basic research and research and development plans of pharmaceutical companies are radically changing the kind of available drugs and therapeutic targets. We are switching from predominantly chemical molecules, aimed at treating large populations of patients (blockbuster drugs), to a new generation of products, mostly biotech, aimed at modifying a specific pathogenetic mechanism. In other word we are moving fast to targeted therapy, which represents the first step toward personalized therapy, where the right drug at the right dose is administered to the right person, at the right time. Like the patent expiration of chemical products has corresponded to the development of generic drugs, the expiration of new biotech products will witness the appearance of biosimilars. The latter are biologic products that are highly similar but not identical to the reference medical products in terms of quality, safety and efficacy. This implies specific research, clinical monitoring, physicians updating of knowledge for a safe and appropriate use of these products. We are the beginning of a devolution in patient's care and physicians' practice.Advances in basic research and research and development plans of pharmaceutical companies are radically changing the kind of available drugs and therapeutic targets. We are switching from predominantly chemical molecules, aimed at treating large populations of patients (blockbuster drugs), to a new generation of products, mostly biotech, aimed at modifying a specific pathogenetic mechanism. In other word we are moving fast to targeted therapy, which represents the first step toward personalized therapy, where the right drug at the right dose is administered to the right person, at the right time. Like the patent expiration of chemical products has corresponded to the development of generic drugs, the expiration of new biotech products will witness the appearance of biosimilars. The latter are biologic products that are highly similar but not identical to the reference medical products in terms of quality, safety and efficacy. This implies specific research, clinical monitoring, physicians updating of knowledge for a safe and appropriate use of these products. We are the beginning of a devolution in patient's care and physicians' practice. Advances in basic research and research and development plans of pharmaceutical companies are radically changing the kind of available drugs and therapeutic targets. We are switching from predominantly chemical molecules, aimed at treating large populations of patients (blockbuster drugs), to a new generation of products, mostly biotech, aimed at modifying a specific pathogenetic mechanism. In other word we are moving fast to targeted therapy, which represents the first step toward personalized therapy, where the right drug at the right dose is administered to the right person, at the right time. Like the patent expiration of chemical products has corresponded to the development of generic drugs, the expiration of new biotech products will witness the appearance of biosimilars. The latter are biologic products that are highly similar but not identical to the reference medical products in terms of quality, safety and efficacy. This implies specific research, clinical monitoring, physicians updating of knowledge for a safe and appropriate use of these products. We are the beginning of a devolution in patient's care and physicians' practice. Advances in basic research and research and development plans of pharmaceutical companies are radically changing the kind of available drugs and therapeutic targets. We are switching from predominantly chemical molecules, aimed at treating large populations of patients (blockbuster drugs), to a new generation of products, mostly biotech, aimed at modifying a specific pathogenetic mechanism. In other word we are moving fast to targeted therapy, which represents the first step toward personalized therapy, where the right drug at the right dose is administered to the right person, at the right time. Like the patent expiration of chemical products has corresponded to the development of generic drugs, the expiration of new biotech products will witness the appearance of biosimilars. The latter are biologic products that are highly similar but not identical to the reference medical products in terms of quality, safety and efficacy. This implies specific research, clinical monitoring, physicians updating of knowledge for a safe and appropriate use of these products. We are the beginning of a devolution in patient's care and physicians' practice. Abstract Advances in basic research and research and development plans of pharmaceutical companies are radically changing the kind of available drugs and therapeutic targets. We are switching from predominantly chemical molecules, aimed at treating large populations of patients (blockbuster drugs), to a new generation of products, mostly biotech, aimed at modifying a specific pathogenetic mechanism. In other word we are moving fast to targeted therapy, which represents the first step toward personalized therapy, where the right drug at the right dose is administered to the right person, at the right time. Like the patent expiration of chemical products has corresponded to the development of generic drugs, the expiration of new biotech products will witness the appearance of biosimilars. The latter are biologic products that are highly similar but not identical to the reference medical products in terms of quality, safety and efficacy. This implies specific research, clinical monitoring, physicians updating of knowledge for a safe and appropriate use of these products. We are the beginning of a devolution in patient's care and physicians' practice. |
| Author | Braido, F. Canonica, G.W. Holgate, S. |
| Author_xml | – sequence: 1 givenname: F. surname: Braido fullname: Braido, F. email: fulvio.braido@unige.it organization: Allergy & Respiratory Diseases Clinic – University of Genoa, IRCCS-AOU San Martino, Pad. Maragliano, Largo Rosanna Benzi 10, 16132 Genova, Italy – sequence: 2 givenname: S. surname: Holgate fullname: Holgate, S. organization: School of Medicine, University of Southampton, III Division, Mail Point 810, Level F, South Block, Southampton General Hospital, Southampton, Hampshire SO16 6YD, UK – sequence: 3 givenname: G.W. surname: Canonica fullname: Canonica, G.W. organization: Allergy & Respiratory Diseases Clinic – University of Genoa, IRCCS-AOU San Martino, Pad. Maragliano, Largo Rosanna Benzi 10, 16132 Genova, Italy |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/23010202$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFks1u1TAQhS1URH_gBVggL1lww9iJc5MKVaoqCkiVWABry3Emqm8dO9hOxd31QeDl-iQ4vYVFJcrGtkbnm7HP8SHZc94hIS8ZFAxY_XZTTPOUCg6MF9AWAOIJOWCC81Vb83Yvn6GtVkKU7T45jHEDAOuqFM_IPi-BAQd-QH6cBz_S25ufnfX6qptjwhBvb37R5O-qxkczGqvuisf01FE_TT6k2Zm0pYMPdFLJoEvxDR2xN1pZGifURlkTU6TK9fQSlU2XVKuAdAr-2vR5xnPydFA24ov7_Yh8O3__9ezj6uLzh09npxcrXdU85dv3ndCA9aCHpgPeMeyauuZl34umAsHbXg2dxkYrbAeBXFWlAugA13VTI5RH5PWub578fcaY5GiiRmuVQz9HyTgHsc5rk6Wv7qVzl98ip2BGFbbyj1tZwHcCHXyMAYe_EgZyiURu5BKJXCKR0MocSYaaB5A2KXvmXQrK2MfRdzsUs0HXBoOMOnuts88BdZK9N4_jJw9wbY1bIrrCLcaNn4PL1ksmY2bkl-W7LL-FcQBW8TI3OP53g_9N_w0nC9Xv |
| CitedBy_id | crossref_primary_10_1186_s12948_015_0010_3 crossref_primary_10_1186_s40413_015_0079_7 crossref_primary_10_1016_S2213_2600_13_70128_0 crossref_primary_10_1093_annonc_mdt325 crossref_primary_10_1097_MCP_0000000000000227 crossref_primary_10_1007_s00228_014_1655_4 crossref_primary_10_3109_02770903_2016_1140774 crossref_primary_10_3389_fimmu_2019_01051 crossref_primary_10_1186_1939_4551_7_6 crossref_primary_10_2478_sjph_2014_0011 crossref_primary_10_3233_JRS_160672 crossref_primary_10_1097_ACI_0000000000000416 crossref_primary_10_1016_j_nurpra_2015_08_027 crossref_primary_10_1097_ACI_0000000000000226 crossref_primary_10_1186_s12948_015_0028_6 crossref_primary_10_1186_s12948_017_0065_4 crossref_primary_10_1080_02770903_2017_1396471 crossref_primary_10_1586_17476348_2016_1111763 crossref_primary_10_1016_j_imlet_2014_08_010 crossref_primary_10_1136_ejhpharm_2013_000293 |
| Cites_doi | 10.1182/blood.V98.12.3241 10.1093/ndt/gfl475 10.1016/j.tips.2010.04.009 10.1016/j.jaci.2007.09.017 10.1007/BF02678211 10.1056/NEJMoa0805435 10.1517/14712591003796553 10.1177/039463201202500217 10.1097/ACI.0b013e32832b4651 10.1093/annonc/mdm345 10.1002/psb.155 10.1056/NEJMp1006304 10.1159/000334701 10.1016/j.jaci.2010.08.024 10.1159/000105133 10.1111/j.1365-2710.2008.00942.x 10.1164/rccm.201103-0396OC 10.1001/jama.300.16.1887 10.1038/nm.2678 10.1056/NEJMoa0808991 10.1056/NEJMoa1106469 |
| ContentType | Journal Article |
| Copyright | 2012 Elsevier Ltd Elsevier Ltd Copyright © 2012 Elsevier Ltd. All rights reserved. |
| Copyright_xml | – notice: 2012 Elsevier Ltd – notice: Elsevier Ltd – notice: Copyright © 2012 Elsevier Ltd. All rights reserved. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1016/j.pupt.2012.09.005 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1522-9629 |
| EndPage | 486 |
| ExternalDocumentID | 23010202 10_1016_j_pupt_2012_09_005 S1094553912001423 1_s2_0_S1094553912001423 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GrantInformation_xml | – fundername: Medical Research Council grantid: G0800766 |
| GroupedDBID | --- --K --M -RU .1- .FO .~1 0R~ 123 1B1 1P~ 1RT 1~. 1~5 29P 4.4 457 4G. 53G 5VS 7-5 71M 8P~ AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AATTM AAXKI AAXUO AAYWO ABBQC ABFRF ABJNI ABMAC ABMZM ABWVN ABXDB ABZDS ACDAQ ACGFS ACIEU ACLOT ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADFGL ADMUD ADNMO AEBSH AEFWE AEIPS AEKER AENEX AEUPX AEVXI AFJKZ AFPUW AFRHN AFTJW AFXIZ AGHFR AGQPQ AGUBO AGYEJ AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALCLG ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CAG COF CS3 DM4 DU5 EBS EFBJH EFKBS EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-Q GBLVA HVGLF HZ~ IHE J1W KOM M41 MO0 N9A O-L O9- OAUVE OGGZJ OI- OU. OZT P-8 P-9 P2P PC. Q38 R2- ROL RPZ SDF SDG SDP SES SEW SPCBC SSH SSP SSZ T5K UHS UNMZH XPP Z5R ZMT ZU3 ~G- ~HD AACTN AFCTW AFKWA AJOXV AMFUW RIG AAIAV AATCM ABLVK ABYKQ AJBFU LCYCR 9DU AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
| ID | FETCH-LOGICAL-c462t-55db5c0e6fcf8b02b1eb86623dd5840529dafbce8cae9f5e2a43a00b0e7686e03 |
| ISICitedReferencesCount | 21 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000312175000012&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1094-5539 1522-9629 |
| IngestDate | Sat Sep 27 21:10:08 EDT 2025 Mon Nov 17 00:34:06 EST 2025 Sat Nov 29 01:31:41 EST 2025 Tue Nov 18 21:46:29 EST 2025 Fri Feb 23 02:34:23 EST 2024 Sun Feb 23 10:18:46 EST 2025 Tue Oct 14 19:31:19 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Keywords | Biotech Biosimilars Asthma |
| Language | English |
| License | https://www.elsevier.com/tdm/userlicense/1.0 Copyright © 2012 Elsevier Ltd. All rights reserved. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c462t-55db5c0e6fcf8b02b1eb86623dd5840529dafbce8cae9f5e2a43a00b0e7686e03 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| PMID | 23010202 |
| PQID | 1220571228 |
| PQPubID | 23479 |
| PageCount | 4 |
| ParticipantIDs | proquest_miscellaneous_1220571228 pubmed_primary_23010202 crossref_primary_10_1016_j_pupt_2012_09_005 crossref_citationtrail_10_1016_j_pupt_2012_09_005 elsevier_sciencedirect_doi_10_1016_j_pupt_2012_09_005 elsevier_clinicalkeyesjournals_1_s2_0_S1094553912001423 elsevier_clinicalkey_doi_10_1016_j_pupt_2012_09_005 |
| PublicationCentury | 2000 |
| PublicationDate | 2012-12-01 |
| PublicationDateYYYYMMDD | 2012-12-01 |
| PublicationDate_xml | – month: 12 year: 2012 text: 2012-12-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | Pulmonary pharmacology & therapeutics |
| PublicationTitleAlternate | Pulm Pharmacol Ther |
| PublicationYear | 2012 |
| Publisher | Elsevier Ltd |
| Publisher_xml | – name: Elsevier Ltd |
| References | Roger (bib11) 2010; 10 Hamburg, Collins (bib4) 2010 Jul 22; 363 Baiardini, Braido, Bonini, Compalati, Canonica (bib1) 2009; 9 Calderón, Casale, Togias, Bousquet, Durham, Demoly (bib30) 2011; 127 Bjermer (bib21) 2007; 120 Castro, Mathur, Hargreave, Boulet, Xie, Young, Res-5-0010 Study Group (bib27) 2011; 184 Oberg, Alm (bib12) 1997; 10 Duerden (bib18) 2007; 18 Riccio, Dal Negro, Micheletto, De Ferrari, Folli, Chiappori (bib24) 2012; 25 Giezen, Mantel-Teeuwisse, Straus, Schellekens, Leufkens, Egberts (bib6) 2008; 300 Li, Yang, Xia, Bertino, Glaspy, Roberts (bib14) 2001; 98 Nair, Pizzichini, Kjarsgaard, Inman, Efthimiadis, Pizzichini (bib26) 2009; 360 PhRMA, CMR, Genentech, Booz, Allen Haneton: The global innovation 1000; 2006. Roger, Goldsmith (bib19) 2008; 33 Nowicki (bib13) 2007; 30 Mellstedt, Niederwieser, Ludwig (bib16) 2008; 19 World Preview to 2012 ; 6 June 2008. EvaluatePharma Haussler (bib20) 2010 Schellekens (bib15) 2004; 3 . Corren, Lemanske, Hanania, Korenblat, Parsey, Arron (bib29) 2011; 365 (bib8) 04 May 2012; 18 (bib3) 2011; 378 Barnes (bib28) 2010; 31 Wenzel (bib22) 2012; 18 Locatelli, Roger (bib17) 2006; 21 Suppl 5 Haldar, Brightling, Hargadon, Gupta, Monteiro, Sousa (bib25) 2009; 360 Hoshino, Ohtawa (bib23) 2012; 83 Giezen (10.1016/j.pupt.2012.09.005_bib6) 2008; 300 (10.1016/j.pupt.2012.09.005_bib3) 2011; 378 (10.1016/j.pupt.2012.09.005_bib8) 2012; 18 Li (10.1016/j.pupt.2012.09.005_bib14) 2001; 98 Baiardini (10.1016/j.pupt.2012.09.005_bib1) 2009; 9 Castro (10.1016/j.pupt.2012.09.005_bib27) 2011; 184 10.1016/j.pupt.2012.09.005_bib7 10.1016/j.pupt.2012.09.005_bib9 Mellstedt (10.1016/j.pupt.2012.09.005_bib16) 2008; 19 Roger (10.1016/j.pupt.2012.09.005_bib11) 2010; 10 Barnes (10.1016/j.pupt.2012.09.005_bib28) 2010; 31 Calderón (10.1016/j.pupt.2012.09.005_bib30) 2011; 127 Haussler (10.1016/j.pupt.2012.09.005_bib20) 2010 10.1016/j.pupt.2012.09.005_bib10 Hamburg (10.1016/j.pupt.2012.09.005_bib4) 2010; 363 Locatelli (10.1016/j.pupt.2012.09.005_bib17) 2006; 21 Suppl 5 Corren (10.1016/j.pupt.2012.09.005_bib29) 2011; 365 Nair (10.1016/j.pupt.2012.09.005_bib26) 2009; 360 Nowicki (10.1016/j.pupt.2012.09.005_bib13) 2007; 30 Haldar (10.1016/j.pupt.2012.09.005_bib25) 2009; 360 Schellekens (10.1016/j.pupt.2012.09.005_bib15) 2004; 3 10.1016/j.pupt.2012.09.005_bib2 Wenzel (10.1016/j.pupt.2012.09.005_bib22) 2012; 18 10.1016/j.pupt.2012.09.005_bib5 Duerden (10.1016/j.pupt.2012.09.005_bib18) 2007; 18 Bjermer (10.1016/j.pupt.2012.09.005_bib21) 2007; 120 Oberg (10.1016/j.pupt.2012.09.005_bib12) 1997; 10 Riccio (10.1016/j.pupt.2012.09.005_bib24) 2012; 25 Hoshino (10.1016/j.pupt.2012.09.005_bib23) 2012; 83 Roger (10.1016/j.pupt.2012.09.005_bib19) 2008; 33 |
| References_xml | – volume: 98 start-page: 3241 year: 2001 end-page: 3248 ident: bib14 article-title: Thrombocytopenia caused by the development of antibodies to thrombopoietin publication-title: Blood – volume: 30 start-page: 267 year: 2007 end-page: 272 ident: bib13 article-title: Basic facts about biosimilars publication-title: Kidney Blood Press Res – reference: EvaluatePharma – volume: 184 start-page: 112 year: 2011 ident: bib27 article-title: Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study publication-title: Am J Respir Crit Care Med – volume: 10 start-page: 1 year: 1997 end-page: 5 ident: bib12 article-title: The incidence and clinical significance of antibodies to interferon-a in patients with solid tumors publication-title: Biotherapy – volume: 9 start-page: 228 year: 2009 end-page: 233 ident: bib1 article-title: Why do doctors and patients not follow guidelines? publication-title: Curr Opin Allergy Clin Immunol – reference: PhRMA, CMR, Genentech, Booz, Allen Haneton: The global innovation 1000; 2006. – volume: 365 start-page: 1088 year: 2011 end-page: 1098 ident: bib29 article-title: Lebrikizumab treatment in adults with asthma publication-title: N Engl J Med – volume: 363 start-page: 301 year: 2010 Jul 22 end-page: 304 ident: bib4 article-title: The path to personalized medicine publication-title: N Engl J Med – volume: 10 start-page: 1011 year: 2010 end-page: 1018 ident: bib11 article-title: Biosimilars: current status and future directions publication-title: Expert Opin Biol Ther – reference: World Preview to 2012 ; 6 June 2008. – volume: 3 start-page: 8 year: 2004 end-page: 12 ident: bib15 article-title: Biosimilar epoetins: how similar are they publication-title: Eur J Hosp Pharm – volume: 19 start-page: 411 year: 2008 end-page: 419 ident: bib16 article-title: The challenge of biosimilars publication-title: Ann Oncol – volume: 33 start-page: 459 year: 2008 end-page: 464 ident: bib19 article-title: Biosimilars: it's not as simple as cost alone publication-title: J Clin Pharm Ther – volume: 18 start-page: 716 year: 2012 end-page: 725 ident: bib22 article-title: Asthma phenotypes: the evolution from clinical to molecular approaches publication-title: Nat Med – volume: 127 start-page: 30 year: 2011 end-page: 38 ident: bib30 article-title: Allergen-specific immunotherapy for respiratory allergies: from meta-analysis to registration and beyond publication-title: J Allergy Clin Immunol – volume: 18 start-page: 636 year: 04 May 2012 ident: bib8 article-title: Nature medicine publication-title: News – volume: 21 Suppl 5 start-page: v13 year: 2006 end-page: 6 ident: bib17 article-title: Comparative testing and pharmacovigilance of biosimilars publication-title: Nephrol Dial Transplant – volume: 360 start-page: 973 year: 2009 end-page: 984 ident: bib25 article-title: Mepolizumab and exacerbations of refractory eosinophilic asthma publication-title: N Engl J Med – reference: . – volume: 120 start-page: 1269 year: 2007 end-page: 1275 ident: bib21 article-title: Time for a paradigm shift in asthma treatment: from relieving bronchospasm to controlling systemic inflammation publication-title: J Allergy Clin Immunol – volume: 83 start-page: 520 year: 2012 end-page: 528 ident: bib23 article-title: Effects of adding omalizumab, an anti-immunoglobulin e antibody, on airway wall thickening in asthma publication-title: Respiration – volume: 378 year: 2011 ident: bib3 article-title: Lessons from Lipitor and the broken blockbuster drug model publication-title: Lancet – volume: 25 start-page: 475 year: 2012 end-page: 484 ident: bib24 article-title: Omalizumab modulates bronchial reticular basement membrane thickness and eosinophil infiltration in severe persistent allergic asthma patient publication-title: Int J Immunopathol Pharmacol – volume: 31 start-page: 335 year: 2010 end-page: 343 ident: bib28 article-title: New therapies for asthma: is there any progress? publication-title: Trends Pharmacol Sci – volume: 300 start-page: 1887 year: 2008 end-page: 1896 ident: bib6 article-title: Safety-related regulatory actions for biologicals approved in the United States and the European Union publication-title: J Am Med Assoc – volume: 18 year: 2007 ident: bib18 article-title: Prescribing advice needed for new biosimilar biological drugs publication-title: Prescriber – volume: 360 start-page: 985 year: 2009 end-page: 993 ident: bib26 article-title: Mepolizumab for prednisone-dependent asthma with sputum eosinophilia publication-title: N Engl J Med – year: 2010 ident: bib20 article-title: Cost savings potential of biosimilars in the German health care system publication-title: Life science in the capital market biosimilars – volume: 98 start-page: 3241 year: 2001 ident: 10.1016/j.pupt.2012.09.005_bib14 article-title: Thrombocytopenia caused by the development of antibodies to thrombopoietin publication-title: Blood doi: 10.1182/blood.V98.12.3241 – volume: 21 Suppl 5 start-page: v13 year: 2006 ident: 10.1016/j.pupt.2012.09.005_bib17 article-title: Comparative testing and pharmacovigilance of biosimilars publication-title: Nephrol Dial Transplant doi: 10.1093/ndt/gfl475 – volume: 378 year: 2011 ident: 10.1016/j.pupt.2012.09.005_bib3 article-title: Lessons from Lipitor and the broken blockbuster drug model publication-title: Lancet – volume: 31 start-page: 335 year: 2010 ident: 10.1016/j.pupt.2012.09.005_bib28 article-title: New therapies for asthma: is there any progress? publication-title: Trends Pharmacol Sci doi: 10.1016/j.tips.2010.04.009 – ident: 10.1016/j.pupt.2012.09.005_bib10 – ident: 10.1016/j.pupt.2012.09.005_bib9 – volume: 120 start-page: 1269 year: 2007 ident: 10.1016/j.pupt.2012.09.005_bib21 article-title: Time for a paradigm shift in asthma treatment: from relieving bronchospasm to controlling systemic inflammation publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2007.09.017 – ident: 10.1016/j.pupt.2012.09.005_bib7 – ident: 10.1016/j.pupt.2012.09.005_bib5 – volume: 10 start-page: 1 year: 1997 ident: 10.1016/j.pupt.2012.09.005_bib12 article-title: The incidence and clinical significance of antibodies to interferon-a in patients with solid tumors publication-title: Biotherapy doi: 10.1007/BF02678211 – volume: 360 start-page: 985 year: 2009 ident: 10.1016/j.pupt.2012.09.005_bib26 article-title: Mepolizumab for prednisone-dependent asthma with sputum eosinophilia publication-title: N Engl J Med doi: 10.1056/NEJMoa0805435 – volume: 10 start-page: 1011 year: 2010 ident: 10.1016/j.pupt.2012.09.005_bib11 article-title: Biosimilars: current status and future directions publication-title: Expert Opin Biol Ther doi: 10.1517/14712591003796553 – volume: 3 start-page: 8 year: 2004 ident: 10.1016/j.pupt.2012.09.005_bib15 article-title: Biosimilar epoetins: how similar are they? publication-title: Eur J Hosp Pharm – volume: 25 start-page: 475 year: 2012 ident: 10.1016/j.pupt.2012.09.005_bib24 article-title: Omalizumab modulates bronchial reticular basement membrane thickness and eosinophil infiltration in severe persistent allergic asthma patient publication-title: Int J Immunopathol Pharmacol doi: 10.1177/039463201202500217 – volume: 9 start-page: 228 year: 2009 ident: 10.1016/j.pupt.2012.09.005_bib1 article-title: Why do doctors and patients not follow guidelines? publication-title: Curr Opin Allergy Clin Immunol doi: 10.1097/ACI.0b013e32832b4651 – volume: 19 start-page: 411 year: 2008 ident: 10.1016/j.pupt.2012.09.005_bib16 article-title: The challenge of biosimilars publication-title: Ann Oncol doi: 10.1093/annonc/mdm345 – volume: 18 year: 2007 ident: 10.1016/j.pupt.2012.09.005_bib18 article-title: Prescribing advice needed for new biosimilar biological drugs publication-title: Prescriber doi: 10.1002/psb.155 – volume: 363 start-page: 301 year: 2010 ident: 10.1016/j.pupt.2012.09.005_bib4 article-title: The path to personalized medicine publication-title: N Engl J Med doi: 10.1056/NEJMp1006304 – volume: 83 start-page: 520 year: 2012 ident: 10.1016/j.pupt.2012.09.005_bib23 article-title: Effects of adding omalizumab, an anti-immunoglobulin e antibody, on airway wall thickening in asthma publication-title: Respiration doi: 10.1159/000334701 – volume: 18 start-page: 636 year: 2012 ident: 10.1016/j.pupt.2012.09.005_bib8 article-title: Nature medicine publication-title: News – volume: 127 start-page: 30 year: 2011 ident: 10.1016/j.pupt.2012.09.005_bib30 article-title: Allergen-specific immunotherapy for respiratory allergies: from meta-analysis to registration and beyond publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2010.08.024 – ident: 10.1016/j.pupt.2012.09.005_bib2 – volume: 30 start-page: 267 year: 2007 ident: 10.1016/j.pupt.2012.09.005_bib13 article-title: Basic facts about biosimilars publication-title: Kidney Blood Press Res doi: 10.1159/000105133 – volume: 33 start-page: 459 year: 2008 ident: 10.1016/j.pupt.2012.09.005_bib19 article-title: Biosimilars: it's not as simple as cost alone publication-title: J Clin Pharm Ther doi: 10.1111/j.1365-2710.2008.00942.x – volume: 184 start-page: 112 year: 2011 ident: 10.1016/j.pupt.2012.09.005_bib27 article-title: Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study publication-title: Am J Respir Crit Care Med doi: 10.1164/rccm.201103-0396OC – volume: 300 start-page: 1887 year: 2008 ident: 10.1016/j.pupt.2012.09.005_bib6 article-title: Safety-related regulatory actions for biologicals approved in the United States and the European Union publication-title: J Am Med Assoc doi: 10.1001/jama.300.16.1887 – volume: 18 start-page: 716 year: 2012 ident: 10.1016/j.pupt.2012.09.005_bib22 article-title: Asthma phenotypes: the evolution from clinical to molecular approaches publication-title: Nat Med doi: 10.1038/nm.2678 – volume: 360 start-page: 973 year: 2009 ident: 10.1016/j.pupt.2012.09.005_bib25 article-title: Mepolizumab and exacerbations of refractory eosinophilic asthma publication-title: N Engl J Med doi: 10.1056/NEJMoa0808991 – volume: 365 start-page: 1088 year: 2011 ident: 10.1016/j.pupt.2012.09.005_bib29 article-title: Lebrikizumab treatment in adults with asthma publication-title: N Engl J Med doi: 10.1056/NEJMoa1106469 – year: 2010 ident: 10.1016/j.pupt.2012.09.005_bib20 article-title: Cost savings potential of biosimilars in the German health care system |
| SSID | ssj0007435 |
| Score | 2.1201813 |
| Snippet | Advances in basic research and research and development plans of pharmaceutical companies are radically changing the kind of available drugs and therapeutic... Abstract Advances in basic research and research and development plans of pharmaceutical companies are radically changing the kind of available drugs and... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 483 |
| SubjectTerms | Asthma Biological Products - administration & dosage Biological Products - adverse effects Biological Products - therapeutic use Biosimilar Pharmaceuticals - administration & dosage Biosimilar Pharmaceuticals - adverse effects Biosimilar Pharmaceuticals - therapeutic use Biosimilars Biotech Drug Design Drug Industry - methods Drug Monitoring - methods Drugs, Generic - administration & dosage Drugs, Generic - therapeutic use Humans Medical Education Molecular Targeted Therapy Patents as Topic Precision Medicine - methods Pulmonary/Respiratory |
| Title | From “blockbusters” to “biosimilars”: An opportunity for patients, medical specialists and health care providers |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S1094553912001423 https://www.clinicalkey.es/playcontent/1-s2.0-S1094553912001423 https://dx.doi.org/10.1016/j.pupt.2012.09.005 https://www.ncbi.nlm.nih.gov/pubmed/23010202 https://www.proquest.com/docview/1220571228 |
| Volume | 25 |
| WOSCitedRecordID | wos000312175000012&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVESC databaseName: ScienceDirect database customDbUrl: eissn: 1522-9629 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0007435 issn: 1094-5539 databaseCode: AIEXJ dateStart: 19970201 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLa6DSFeEIxbuUxGQntZgxI3V96q0jFuUyWK6JsVJ46U0SVV007lbT8EfhH_Yr-Ec2InTRkdF4mXqHLtxsn31f6Ofc4xIc_AokgsLwkMl8XMsO3EM0TkMUOC1oiFjRtfJdLvvONjfzwOhq3W9yoW5mziZZm_XAbT_wo1lAHYGDr7F3DXPwoF8BlAhyvADtc_Av4QA0YqH4a-gMnqs1hgOoSiKnyJgnNVI82L9DRFC7euoJcL8ymq80WWardOnYS1hP5U7_AU6gB7YIvK9qwCK8uM1wdVmF_RlMDDxQTeBTrrTVdps5XfTiMYbLV6PwvTOF_zQT7KJ7j4t7Zw2w8zTPJbSuFXzz81FzMs1nAMUeMvWJuG46j8RtUArSKjNRGbo62tzsDRE7etcmpfmhPU8sQJ8HuKzrO4-Is5Sp3VDFjt-g_6by2jgO-ND9gR7IeFPmc2665XVuYTLxg3-aWqW2SHeU4AQ-xO7_Vg_KYWBiDWnHLzXT-jjuFS7oY_926TTtpkB5V6aHSL3NSGDO0pAt4mLZntkuvvtavGLtkfKnS_dOioAWuH7tNhA_c7ZImEpRfnX5tUvTj_Rud5WbqiJxS-oL2MNmhJgZa0omWHalLSBikpkJIqUlIkJa1JeZd8PByM-keGPg_EiGyXzeGdxcKJTOkmUeILkwlLCt8F_R7HIKNxyzoOExFJPwplkDiShXY3NE1hSrCpXWl275Ft4KJ8QKjLPFfI0AvMCCR1IAJbJmHkMBkJMJndsE2s6u3zSCfLxzNbJrzyijzhiBhHxLgZcECsTQ7qNlOVKubK2t0KVF4FQcO0zYG1V7byftVKFnoAKvgmVraJU7fU4lqJ5t_e8WnFOA4zD24nhpnMF3AnjNH34Oq3yX1Fxfq5WRdzVZrs4T_39xG5sRogHpPt-Wwhn5Br0dk8LWZ7ZMsb-3v6D_YDqQMJVQ |
| linkProvider | Elsevier |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=From+%E2%80%9Cblockbusters%E2%80%9D+to+%E2%80%9Cbiosimilars%E2%80%9D%3A+An+opportunity+for+patients%2C+medical+specialists+and+health+care+providers&rft.jtitle=Pulmonary+pharmacology+%26+therapeutics&rft.au=Braido%2C+F&rft.au=Holgate%2C+S&rft.au=Canonica%2C+G.W&rft.date=2012-12-01&rft.issn=1094-5539&rft.volume=25&rft.issue=6&rft.spage=483&rft.epage=486&rft_id=info:doi/10.1016%2Fj.pupt.2012.09.005&rft.externalDBID=ECK1-s2.0-S1094553912001423&rft.externalDocID=1_s2_0_S1094553912001423 |
| thumbnail_m | http://cvtisr.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F10945539%2FS1094553912X00075%2Fcov150h.gif |